bioinformatics
January 18, 2012 source: MedCity News Personalized medicine company AssureRx Health has released the next-generation version of its genetic screening test for psychiatric drugs. The Cincinnati-area company’s GeneSightRx test, which helps doctors pick the right psychiatric drugs for patients based on their genes, was launched in 2009. The test uses a cheek swab, mathematical […]
Read More
September 9, 2011 source: originally published in the San Francisco Business Times Gene Security Network’s race to develop safer, more accurate prenatal test is all business for Matt Rabinowitz — and it’s personal. A relative of Rabinowitz, Gene Security Network’s CEO, took a blood test for the likelihood of Down’s syndrome in her unborn baby and […]
Read More
Claremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If […]
Read More
It is always great to brag and cheer about one of our portfolio companies. Working with portfolio companies to help them succeed is one of a VC’s key jobs, and helping build an executive team is an area where a VC can help a lot. We are pleased to announce that AssureRx Health has just […]
Read More
Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult business environment. These challenges include the cost-efficient development of technology that is truly disruptive yet cost-competitive. Panelists will discuss how to best determine […]
Read MoreJuly 1, 2011 source: Genetic Engineering & Biotechnology News by Brad Webb Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. […]
Read MoreMeet our team
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.
NAT GOLDHABER
Nat Goldhaber is a co-founder of Claremont Creek Ventures.
BRAD WEBB
Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.
RANDY HAWKS
Randy Hawks is a co-founder of Claremont Creek Ventures.